Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticip ...
The Company's common shares will continue to trade on Nasdaq under the symbol "NGEN"No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading acc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results